Inside PIC/S: Implementing Quality Risk Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Implementing Quality Risk Management
Representatives to the PIC/S provide an example of methodology for implementing ICH Q9.


Pharmaceutical Technology
Volume 33, Issue 12

Implementing the methodology

The PIC/S example of methodology provides pharmaceutical manufacturers with the means, including training tools and a starter kit, to implement quality risk management. The methodology relies on an interactive database that is accessible to industry.


Figure 1: Diagram of a sample operation in service. CAPA is corrective and preventive action. QRM is quality risk management. GMP is good manufacturing practice. (FIGURE 1 IS COURTESY OF THE AUTHORS)
This service, expected to be available soon, will be hosted and maintained on an independent platform that brings together industry, professional associations, and other pharmaceutical manufacturing partners. Drug manufacturers will be able to voluntarily integrate the system on a customer-supplier basis (see Figure 1).

The platform will make available the assistance necessary to implement the method, guarantee confidentiality, and use the information supplied exclusively for implementing the risk-management methodology.

Future prospects

The informal PIC/S working group has performed beta-tests on the proposed methodology. The methodology will, however, need to be placed under change-control management to achieve continuous improvement.

PIC/S will finalize and implement the example of methodology, possibly by the end of 2010.

Read more about the Pharmaceutical Inspection Cooperation Scheme at http://PharmTech.com/pics/ and http://www.picscheme.org/.

Lionel Viornery is an inspector and head of the starting materials inspection unit at the French Health Products Safety Agency (Afssaps), 143/147, bd Anatole, Saint Denis cedex, 93285, France,
. Philippe Legoff is managing director of H&LG Consultants, Biolleyre 5, CH-1066 Epalinges, Switzerland,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here